FierceHealthcareFierceHealthITFierceHealthFinanceHospital Impact   FiercePharmaFierceBiotechFierceSarbox
About | Sample | Privacy

Glaxo: Avandia critic should pay for stock drop

Tools
Tags
cardiologist
Cleveland Clinic
findings
Food and Drug Administration (FDA)
GlaxoSmithKline

A researcher and early critic of Avandia told Congress yesterday that a GlaxoSmithKline executive threatened him with dire financial consequences when he raised concerns about the drug. Dr. John Buse, who testified before a House panel yesterday, told investigators that Glaxo executive Dr. Tadataka Yamada suggested that he should be responsible for the $4 billion drop in stock value Glaxo suffered after Avandia safety concerns came to light. In light of similar findings by Dr. Steven Nissen, a Cleveland Clinic cardiologist, the FDA is now asking Glaxo--as well as Actos maker Takeda--to put "black box" warnings on the popular drugs. Nissen's findings suggest that Avandia, Glaxo's drug, increases a patient's odds of suffering a heart attack.

To learn more about Buse's concerns:
- read this article from The Boston Globe

Related Articles:
Avandia critic says that FDA launched a smear campaign against him. Report
Avandia controversy sparks FDA criticism. Report
Diabetes expert issued harsh Avandia critique in 2000. Report

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 27 + 62?
To combat spam, please solve the math question above.